Body fluids

Plasma Needed from Donors Who Recovered From COVID-19 for Expanded Access Treatment Program at HSS

Retrieved on: 
Saturday, April 18, 2020
Anatomy, Body fluids, Physical sciences, Transfusion medicine, Blood, Hematology, Blood plasma, Plasma, Food and Drug Administration

HSS is now a participating site in a nationwide program testing convalescent plasma, a treatment that involves infusing hospitalized patients with antibody-rich plasma donated by people who have recovered from the disease.

Key Points: 
  • HSS is now a participating site in a nationwide program testing convalescent plasma, a treatment that involves infusing hospitalized patients with antibody-rich plasma donated by people who have recovered from the disease.
  • Convalescent plasma has been tried as a treatment approach during other pandemics, including the Spanish flu of 1918 to 1920.
  • Hospitals can seek approval from the FDA to use convalescent plasma on an emergency, case-by-case basis or by enrolling in expanded access programs.
  • The expanded access program at HSS is part of a large national study led by the Mayo Clinic.

The global blood plasma market is projected to register a CAGR of 6.24% during the forecast period, 2020-2028

Retrieved on: 
Wednesday, April 15, 2020
Blood, Anatomy, Body fluids, Hematology, Transfusion medicine, Blood plasma, Serum albumin, Plasma, Blood donation, Canadian Plasma Resources, Blood proteins

The global blood plasma market is projected to register a CAGR of 6.24% during the forecast period, 2020-2028.

Key Points: 
  • The global blood plasma market is projected to register a CAGR of 6.24% during the forecast period, 2020-2028.
  • Plasma is essential for the regulation of body functions.Blood Plasma comprises of several components that are useful, like coagulation factors, immunoglobulin, protease inhibitors, and albumin.
  • The market faces challenges like a lack of a safe blood donor base, along with the shortage of plasma fractionation facilities.
  • The global blood plasma market is segregated geographically into Europe, North America, Asia Pacific, and the rest of the world, for further analysis.The North American region held the largest market share in 2019.

Convalescent Plasma Collected in the Carolinas

Retrieved on: 
Monday, April 6, 2020
Infectious diseases, Health, Science, Research, Clinical trials, Hematology, Transfusion medicine, Anatomy, Body fluids, Branches of biology, Blood plasma, Blood donation, Blood, Plasma

The blood product, known as convalescent plasma , may have antibodies that can help those critically ill from COVID-19 to fight the virus.

Key Points: 
  • The blood product, known as convalescent plasma , may have antibodies that can help those critically ill from COVID-19 to fight the virus.
  • Blood donation is a wonderful way to give back and this convalescent plasma program is another way to help save lives in your community, said Delisa English, CEO and President of The Blood Connection.
  • If you have recovered from COVID-19, please consider donating plasma to help with the research that will help others to fight this virus.
  • If you are interested in donating convalescent plasma, please make an appointment at a center near you by calling The Blood Connection at (864)751-1168.

DGAP-News: Biotest AG: Biotest produces life-saving medicine derived from plasma from healed COVID-19 patients and participates in a cross-industry initiative

Retrieved on: 
Monday, April 6, 2020
Anatomy, Branches of biology, Body fluids, Transfusion medicine, Hematology, Blood products, Blood, Blood plasma, Hyperimmune, Coronavirus

Thanks to the willingness of many people to donate plasma, Biotest is able to guarantee the protection of critically ill patients.

Key Points: 
  • Thanks to the willingness of many people to donate plasma, Biotest is able to guarantee the protection of critically ill patients.
  • This is particularly important for high-risk patients who rely on Biotest medicines, e.g.
  • Biotest is, therefore, working to collect plasma from donors who have raised antibodies against coronavirus as quickly as possible.
  • In addition, Biotest is working intensively on a new drug against COVID-19 derived from hyperimmune plasma.

LFB Announces FDA Approval of SEVENFACT®, a New Recombinant Coagulation Factor VIIa, for the Treatment of Adults and Adolescents with Hemophilia A or B with Inhibitors

Retrieved on: 
Monday, April 6, 2020
Research, Hospitals, FDA, Genetics, Clinical trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Blood, Body fluids, Anatomy, Coagulation system, Bleeding, Haemophilia, Transfusion medicine, RTT, Coagulation, Coagulopathy, Haemophilia A, Jeanne Lusher

Denis Delval LFBs Chairman and Chief Executive Officer, stated: We are very pleased with the FDA approval of SEVENFACT which provides a new treatment option for hemophilia patients.

Key Points: 
  • Denis Delval LFBs Chairman and Chief Executive Officer, stated: We are very pleased with the FDA approval of SEVENFACT which provides a new treatment option for hemophilia patients.
  • We will now work towards SEVENFACT registration in Europe and other core countries, in order to offer this therapeutic option to patients.
  • Hemophilia A or B is a congenital bleeding disorder caused by a dysfunction or deficiency of Coagulation Factor (F) VIII or IX, respectively.
  • People with Hemophilia may bleed for a longer time than others after injury or surgery.

FDA Approves Additional Treatment for Adults and Adolescents with Hemophilia A or B and Inhibitors

Retrieved on: 
Wednesday, April 1, 2020
Blood, Body fluids, Anatomy, Coagulation system, Haemophilia, Transfusion medicine, RTT, Coagulation, Bleeding, Haemophilia A, Coagulopathy, Jeanne Lusher

"Today's approval provides another treatment option for the control of bleeding episodes in adults and adolescents with hemophilia who have developed inhibitors," said Dr. Peter Marks, M.D., Ph.D., director of the FDA's Center for Biologics Evaluation and Research.

Key Points: 
  • "Today's approval provides another treatment option for the control of bleeding episodes in adults and adolescents with hemophilia who have developed inhibitors," said Dr. Peter Marks, M.D., Ph.D., director of the FDA's Center for Biologics Evaluation and Research.
  • Hemophilia A or B is a congenital bleeding disorder caused by a dysfunction or deficiency of Coagulation Factor (F) VIII or IX, respectively.
  • People with hemophilia may bleed for a longer time than others after injury or surgery.
  • Another study evaluated the safety and pharmacokinetics of three escalating doses of Sevenfactin 15 patients with severe hemophilia A or B with or without inhibitors.

Cryo-Cell Confirms Specimen Longevity of 23+ Years with Optimal CD34 Viability

Retrieved on: 
Friday, March 13, 2020
Stem cells, Branches of biology, Blood, Body fluids, Anatomy, Childbirth, Cord blood bank, Sibling, Cryo-Cell International, Cord blood, Blood bank

Cryo-Cell International marks the first family cord blood bank to release results concerning specimen viability for this length of time.

Key Points: 
  • Cryo-Cell International marks the first family cord blood bank to release results concerning specimen viability for this length of time.
  • Since cord blood banking has only been in existence for 30 years, these findings indicate that specimen longevity nearly spans the lifetime of the industry.
  • Research points to the idea that other cryogenically preserved cells remain undiminished by time, as long as cells are preserved at optimal storage temperature, where cellular activity is known to halt.
  • Statements wherein the terms "believes", "intends", "projects", "anticipates", "expects", and similar expressions as used are intended to reflect "forward-looking statements" of the Company.

Coronavirus Fears Puts Nation’s Blood Supply at Risk

Retrieved on: 
Tuesday, March 10, 2020
Hematology, Medical specialties, Transfusion medicine, Body fluids, Blood donation, Blood

As coronavirus fears intensify, blood centers around the country are experiencing a significant decrease in donations and blood drives are being canceled, said Kate Fry, CEO of Americas Blood Centers, an organization that represents nearly 50 blood centers throughout the United States and Canada, and collects close to 60% of the nations blood supply.

Key Points: 
  • As coronavirus fears intensify, blood centers around the country are experiencing a significant decrease in donations and blood drives are being canceled, said Kate Fry, CEO of Americas Blood Centers, an organization that represents nearly 50 blood centers throughout the United States and Canada, and collects close to 60% of the nations blood supply.
  • The coronavirus does not pose any known risk to blood donors during the donation process or from attending blood drives
    There is growing concern that if the coronavirus continues to spread it could potentially reduce the number of eligible donors and put the blood supply at risk.
  • Every blood center is now actively preparing for the possibility that the entire country can be affected by the coronavirus and the impact this will have on the nations blood supply.
  • The blood supply cannot be taken for granted and the coronavirus only heightens the need for a ready blood supply.

FDA grants South Texas Blood & Tissue Center first license for new process that triples shelf life of critically needed platelets

Retrieved on: 
Friday, February 28, 2020
Blood, Branches of biology, Transfusion medicine, Body fluids, Hematology, Blood products, Coagulation system, In science, Platelet, Plateletpheresis, Blood bank

San Antonio, Texas, Feb. 28, 2020 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration has granted the South Texas Blood & Tissue Center (STBTC) a license to use a new process shown to almost triple the current five-day shelf life of platelets.

Key Points: 
  • San Antonio, Texas, Feb. 28, 2020 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration has granted the South Texas Blood & Tissue Center (STBTC) a license to use a new process shown to almost triple the current five-day shelf life of platelets.
  • STBTC, a subsidiary of BioBridge Global, is the first blood center in the United States to receive an FDA license to produce the licensed cold-stored platelets.
  • With this new process, platelets are refrigerated within two hours of collection, which extends their viability to 14 days.
  • About the South Texas Blood & Tissue Center:
    The South Texas Blood & Tissue Center (STBTC) is a nonprofit community blood center that provides blood, plasma, platelets and other blood components to 100 hospitals in 48 South Texas counties.

Hemophilia A - Forecasts for Seven Major Markets Covering the United States, EU5 and Japan

Retrieved on: 
Wednesday, February 26, 2020
Blood, Coagulation system, Body fluids, Haemophilia, Anatomy, RTT, Factor VII, Coagulation, Jeanne Lusher

The "Hemophilia A- Epidemiology - 2030" report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Hemophilia A in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Key Points: 
  • The "Hemophilia A- Epidemiology - 2030" report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Hemophilia A in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The treatment of Hemophilia A is mainly focused on the prophylaxis as there is no cure for hemophilia A.
  • Treatment consists of replacing the missing clotting protein (factor VIII) and preventing the complications associated with the disorder.
  • The report provides insight about the historical and forecasted patient pool for seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan.